Monday, October 15, 2012 6:48:13 PM
Mr. Funtleyder makes that assertion near the end of this video on Bloomberg.
http://us.rd.yahoo.com/finance/external/bloomberg/SIG=1335p4e22/*http://www.bloomberg.com/video/funtleyder-on-lilly-s-alzheimer-s-drug-nWW6TV~eTdmCZYnGfrGxjg.html?cmpid=yhoo
__________________________________________________________
"An experimental Alzheimer's treatment from Eli Lilly & Co. slowed memory loss by 42% in patients with a mild form of the memory-robbing disease in one drug trial and showed positive signs of doing so in another study, according to new data presented on Monday.
The results, although mixed, bolster hopes that a drug like Lilly's solanezumab could stymie Alzheimer's destructive march in patients in the early stage of the disease. Current therapies do nothing more than treat the symptoms. Yet more studies probably will be needed to reach a firm conclusion.
"Our next step is to talk to the regulators to see what this means, although we think this is a step forward in getting to a treatment for Alzheimer's," David Ricks, president of Lilly Bio-Medicines, said in an interview.
http://online.wsj.com/article/SB10000872396390444897304578044520966644406.html
FEATURED POET Announces Design Win and Collaboration with Foxconn Interconnect Technology for High-speed AI Systems • May 14, 2024 10:09 AM
FEATURED Element79 Gold Corp Reports Exceptionally High-Grade Results from Lucero • May 14, 2024 7:00 AM
VAYK Added New Manager for Expansion into $64 Billion Domestic Short-term Rental Market • VAYK • May 14, 2024 9:00 AM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM